Details of the Drug
General Information of Drug (ID: DMHZCLV)
Drug Name |
N-Propargyl-1(S)-Aminoindan
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
185517-74-2; (S)-N-(2-Propynyl)-2,3-dihydroinden-1-amine; TVP1022; N-PROPARGYL-1(S)-AMINOINDAN; (S)-Rasagiline; J-500397; S-PAI; AC1NRD1Z; N-propargyl-1-(s)aminoindan; SCHEMBL332967; CHEMBL1235738; BDBM11000; (S)-N-2-propynyl-1-indanamine; RUOKEQAAGRXIBM-LBPRGKRZSA-N; MolPort-006-666-243; KS-00000LL3; ZINC19875505; ANW-23242; FCH907116; AKOS024256741; TV-1022; DB03894; AJ-75608; AS-32581; HY-14200; CJ-16483; AC-14138; TVP1022, > TC-111987; AB0052190; FT-0694134; FT-0674331; V3968; (1S)-N-methyl-N-prop-2-ynyl-indan-1-amine
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 171.24 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||